Asymmetric hydrogenation of a 4,4-diaryl-3-butenoate; a novel approach to sertraline
Published in Organic & Biomolecular Chemistry • Mar 11, 2003
Authors:
Lee T. Boulton
,
Ian C. Lennon
,
Raymond McCague
Abstract
The asymmetric hydrogenation of a selectively crystallised (E)-4,4-diaryl-3-butenoate with a rhodium-PhanePhos catalyst is described, providing an intermediate to the antidepressant sertraline.
